188 related articles for article (PubMed ID: 23174752)
1. Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?
Ross AH; Donachie PH; Sallam A; Stratton IM; Mohamed Q; Scanlon PH; Kirkpatrick JN; Johnston RL
Eye (Lond); 2013 Jan; 27(1):56-64. PubMed ID: 23174752
[TBL] [Abstract][Full Text] [Related]
2. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity.
Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group
Ophthalmology; 2014 May; 121(5):1092-101. PubMed ID: 24461586
[TBL] [Abstract][Full Text] [Related]
3. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
[TBL] [Abstract][Full Text] [Related]
4. Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12.
Williams TA; Blyth CP
Eye (Lond); 2011 Dec; 25(12):1617-21. PubMed ID: 21921947
[TBL] [Abstract][Full Text] [Related]
5. The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes.
Zarranz-Ventura J; Liew G; Johnston RL; Xing W; Akerele T; McKibbin M; Downey L; Natha S; Chakravarthy U; Bailey C; Khan R; Antcliff R; Armstrong S; Varma A; Kumar V; Tsaloumas M; Mandal K; Bunce C; Tufail A;
Ophthalmology; 2014 Oct; 121(10):1966-75. PubMed ID: 24953791
[TBL] [Abstract][Full Text] [Related]
6. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
Spielberg L; Leys A
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
[TBL] [Abstract][Full Text] [Related]
7. UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12.
Lee AY; Lee CS; Butt T; Xing W; Johnston RL; Chakravarthy U; Egan C; Akerele T; McKibbin M; Downey L; Natha S; Bailey C; Khan R; Antcliff R; Varma A; Kumar V; Tsaloumas M; Mandal K; Liew G; Keane PA; Sim D; Bunce C; Tufail A;
Br J Ophthalmol; 2015 Aug; 99(8):1045-50. PubMed ID: 25680619
[TBL] [Abstract][Full Text] [Related]
8. Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia.
Jaki Mekjavić P; Gregorčič B; Oberč C; Podgoršek S
BMC Ophthalmol; 2018 Dec; 18(1):333. PubMed ID: 30572850
[TBL] [Abstract][Full Text] [Related]
9. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.
Ying GS; Huang J; Maguire MG; Jaffe GJ; Grunwald JE; Toth C; Daniel E; Klein M; Pieramici D; Wells J; Martin DF;
Ophthalmology; 2013 Jan; 120(1):122-9. PubMed ID: 23047002
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of intravitreal ranibizumab for neovascular age-related macular degeneration in a well defined region of the UK.
Buckle M; Donachie PH; Johnston RL
Br J Ophthalmol; 2016 Feb; 100(2):240-5. PubMed ID: 26124462
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United Kingdom.
Buckle M; Lee A; Mohamed Q; Fletcher E; Sallam A; Healy R; Stratton I; Tufail A; Johnston RL
Eye (Lond); 2015 Mar; 29(3):403-8. PubMed ID: 25592123
[TBL] [Abstract][Full Text] [Related]
12. Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision.
Shona O; Gupta B; Vemala R; Sivaprasad S
Clin Exp Ophthalmol; 2011 Jan; 39(1):5-8. PubMed ID: 21040311
[TBL] [Abstract][Full Text] [Related]
13. Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration.
Arnold JJ; Campain A; Barthelmes D; Simpson JM; Guymer RH; Hunyor AP; McAllister IL; Essex RW; Morlet N; Gillies MC;
Ophthalmology; 2015 Jun; 122(6):1212-9. PubMed ID: 25846847
[TBL] [Abstract][Full Text] [Related]
14. FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity.
Monés J; Biarnés M; Trindade F; Casaroli-Marano R
Graefes Arch Clin Exp Ophthalmol; 2012 Dec; 250(12):1737-44. PubMed ID: 22527314
[TBL] [Abstract][Full Text] [Related]
15. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
[TBL] [Abstract][Full Text] [Related]
16. Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry.
Bhandari S; Nguyen V; Arnold J; Young S; Banerjee G; Gillies M; Barthelmes D
Ophthalmology; 2020 Mar; 127(3):369-376. PubMed ID: 31757494
[TBL] [Abstract][Full Text] [Related]
17. Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).
Chan CK; Jain A; Sadda S; Varshney N
Trans Am Ophthalmol Soc; 2014 Jul; 112():160-98. PubMed ID: 25646034
[TBL] [Abstract][Full Text] [Related]
18. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Busbee BG; Ho AC; Brown DM; Heier JS; Suñer IJ; Li Z; Rubio RG; Lai P;
Ophthalmology; 2013 May; 120(5):1046-56. PubMed ID: 23352196
[TBL] [Abstract][Full Text] [Related]
19. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
20. Importance of continuous treatment with intravitreal aflibercept injections in patients with neovascular age-related macular degeneration-12-month post hoc analysis of the PERSEUS real-world evidence study.
Wachtlin J; Eter N; Hasanbasic Z; Keramas G; Rech C; Sachs H; Schilling H; Wiedemann P; Framme C
Graefes Arch Clin Exp Ophthalmol; 2021 Mar; 259(3):601-611. PubMed ID: 32789651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
